Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Torsten Zuberbier, Amir Hamzah Abdul Latiff, Mohamed Abuzakouk et al. · Allergy · 2021 · 1.2K citations · Full text

Life Sciences, Dermatology, Immunology +16

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

Marcus Maurer, Karin Rosén, Hsin-Ju Hsieh et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

Allen P. Kaplan, Dennis K. Ledford, Mark Ashby et al. · Journal of Allergy and Clinical Immunology · 2013 · 559 citations

Life Sciences, Immunology, Pharmacotherapy +11

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

Sarbjit S. Saini, Carsten Bindslev‐Jensen, Marcus Maurer et al. · Journal of Investigative Dermatology · 2014 · 460 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +11

The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from <scp>ASSURE</scp>‐<scp>CSU</scp>

Marcus Maurer, Mohamed Abuzakouk, F. Bérard et al. · Allergy · 2017 · 348 citations · Full text

Pharmacy, Dermatology, Allergy +16